Literature DB >> 28606970

The dynamics of response as measured by multiple composite outcome tools in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial.

Laura C Coates1,2, Farrouq Mahmood3, Paul Emery1,2, Philip G Conaghan1,2, Philip S Helliwell1,2,3.   

Abstract

BACKGROUND: We aimed to evaluate the dynamics of treatment response with different composite measures in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial.
METHODS: Participants with early disease-modifying antirheumatic drug-naïve psoriatic arthritis (PsA) were randomised 1:1 to either tight control (TC; 4 weekly review with therapy escalation if criteria not met) or standard care (SC; 12 weekly review). We calculated modified versions of the Psoriatic ArthritiS Disease Activity Score (PASDAS), Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite scorE (GRACE) and Composite Psoriatic Disease Activity Index (CPDAI) at baseline and 12 weekly to 48 weeks by blinded assessor. For missing data, we used the last observation carried forward. Comparison between groups was made by analysis of covariance and comparison of area under the curve (AUC).
RESULTS: 206 people were randomised to TC (n=101) or SC (n=105). Significant differences between treatment groups were seen (p<0.0001 for all composite measures). AUC analysis demonstrated a significant difference between groups for the PASDAS but not GRACE and CPDAI. For participants with oligoarthritis, a significant difference between groups was seen for each measure, although the significance levels were greatly diminished (PASDAS, p=0.04; GRACE p=0.01; CPDAI p=0.04). For oligoarthritis using AUC analysis, none of the measures could distinguish between groups.
CONCLUSIONS: Composite measures of disease activity were able to distinguish between TICOPA treatment arms, although differences were diminished for those with oligoarthritis. Further data are needed to inform the preferred composite measure for use as the primary outcome in PsA trials. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov (NCT01106079) and ISCRCTN registry (ISCRCTN30147736). © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  composite measures; disease activity; outcome assessment; psoriatic arthritis; treatment

Mesh:

Substances:

Year:  2017        PMID: 28606970     DOI: 10.1136/annrheumdis-2017-211137

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  5 in total

Review 1.  Measuring Outcomes in Psoriatic Arthritis.

Authors:  Alexis Ogdie; Laura C Coates; Philip Mease
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-10       Impact factor: 4.794

2.  Methotrexate for psoriatic arthritis.

Authors:  Tom D Wilsdon; Samuel L Whittle; Tilenka Rj Thynne; Arduino A Mangoni
Journal:  Cochrane Database Syst Rev       Date:  2019-01-18

3.  Oligoarticular Psoriatic Arthritis: Addressing Clinical Challenges in an Intriguing Phenotype.

Authors:  Antonio Marchesoni
Journal:  Rheumatol Ther       Date:  2018-06-01

4.  Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.

Authors:  Philip Helliwell; Laura C Coates; Oliver FitzGerald; Peter Nash; Enrique R Soriano; M Elaine Husni; Ming-Ann Hsu; Keith S Kanik; Thijs Hendrikx; Joseph Wu; Elizabeth Kudlacz
Journal:  Arthritis Res Ther       Date:  2018-10-29       Impact factor: 5.156

5.  Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis.

Authors:  Laura C Coates; Joseph F Merola; Philip J Mease; Alexis Ogdie; Dafna D Gladman; Vibeke Strand; Leonieke J J van Mens; Lyrica Liu; Priscilla K Yen; David H Collier; Gregory Kricorian; James B Chung; Philip S Helliwell
Journal:  Rheumatology (Oxford)       Date:  2021-03-02       Impact factor: 7.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.